Rapid disease progression after discontinuation of lenvatinib in thyroid cancer

Some thyroid cancer patients experience a rapid disease progression after the discontinuation of tyrosine kinase inhibitors (TKIs), which is called flare phenomenon. The incidence of the flare phenomenon of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) ranged from 4% to 11....

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Haruhiko, Sugino, Kiminori, Matsuzu, Kenichi, Masaki, Chie, Akaishi, Junko, Hames, Kiyomi, Tomoda, Chisato, Suzuki, Akifumi, Uruno, Takashi, Ohkuwa, Keiko, Kitagawa, Wataru, Nagahama, Mitsuji, Masuda, Munetaka, Ito, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220477/
https://www.ncbi.nlm.nih.gov/pubmed/32176066
http://dx.doi.org/10.1097/MD.0000000000019408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220477/
https://www.ncbi.nlm.nih.gov/pubmed/32176066
http://dx.doi.org/10.1097/MD.0000000000019408

Ejemplares similares